Danaparoid

Danaparoid (Orgaran mean MW, 6,000 Da) is a mixture of nonheparin glycosaminoglycans derived from pig gut (dermatan sulfate, heparan sulfate, chondroitin sulfate). Die anti-Xa/anti-IIa ratio (22 1) is even greater than seen with LMWH. Die anti-IIa effect may be mediated in part by dermatan sulfate, which catalyzes thrombin inhibition by heparin cofactor II. [Pg.110]

Fondaparinux, the factor Xa-binding pentasaccharide (Arixtra, MW 1,728 Da), is prepared synthetically, unlike UFH, LMWH and danaparoid, which are obtained from animal sources. Despite only inactivating free factor Xa, clinical trials indicate that fondaparinux is an effective antithrombotic agent, both for venous thromboembolism prophylaxis and treatment, as well as for acute coronary syndrome and ST elevation myocardial infarction [4]. [Pg.110]

Cytotoxic Agents Cytotoxic T-cells Danaparoid (Heparinoid)... [Pg.1490]

Danaparoid sodium Prepared from animal gut mucosa contains heparin sulfate (84%), dermatan sulfate (12%), and chondroitin sulfate (4%)... [Pg.139]

The Trial of Org 10172 in Acute Stroke Treatment (TOAST) was a randomized, double-blind, placebo-controlled trial of danaparoid in 1281 patients within 24 hours of onset of acute ischemic stroke. A three-stage dosage regime was used to achieve plasma anti-factor Xa activity of 0.8 unit/mL. Favorable outcome was defined as the combination of a Glasgow Outcome Scale (GOS) score of 1 or 2 and a modified Barthel Index (BI) score of 12 or greater (on a scale of 0-20) at 3 months or 7 days. Very favorable outcome required the combination of a GOS score of 1 and a Barthel Index (BI) score of 19 or 20 at 3 months or 7 days. [Pg.140]

Acute Anticoagulation for AF-associated Stroke HAEST and 1ST provided valuable data on relatively large numbers (449 in HAEST, 3169 in 1ST) of patients with AF-associated ischemic stroke treated with acute anticoagulation (danaparoid in HAEST, UFH in 1ST). HAEST found no reduction in early stroke recurrence or effect on late functional outcome in the LMWH arm. In contrast, 1ST found a dose-dependent reduction in early recurrence rates, but no late functional benefit associated with UFH. However, this was offset by an increase in rates of sICH among patients with AF receiving UFH, with no net benefit in the composite outcome of recurrence stroke and sICH combined. The reasons for the discrepancy between trials is unclear. [Pg.150]

Anticoagulation in Stroke Due to LAA Disease Few clinical trials have been performed in this population. In the TOAST trial, a secondary analysis in patients with stroke due to LAA found favorable outcomes at 7 days in 54% of danaparoid-treated patients, compared to 38% of the placebo-treated group (p = 0.02). At 3 months, 68% of patients in the danaparoid group compared to 53% of those in the placebo group had favorable outcomes (p = 0.02). [Pg.152]

Publications Committee for the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid ORG 10172 (Danaparoid) and outcome after acute ischemic stroke. JAMA 1998 279 1265-1272. [Pg.157]

Danaparoid (Orgaran) Anticoagulant LMW heparin Antiestrogenic I Muscle relaxant... [Pg.17]

Danaparoid although sometimes considered as a low molecular weight heparin is chemically distinct from heparin and thus has little cross-reactivity in heparin-intolerant patients. [Pg.371]

LMWH is available for subcutaneous administration as enoxaparin (Lovenox), dalteparin (Fragmin), ardeparin (Normiflo), and tinzaparin (Innohep). Dana-paroid (Orgar an), a heparinoid composed of heparin sulfate, dermatan sulfate, and chondroitin sulfate, has greater factor Xa specificity than LMWH. Bleeding due to danaparoid is not reversed by protamine. [Pg.260]

Ancrod Heparan sulfate Danaparoid Lepirudin 2 U/kg IV infusion... [Pg.244]

Danaparoid containing mainly heparan sulfate isolated from porcine intestinal mucosa and is used in heparin induced thrombocytopenia and deep venous thrombosis. [Pg.245]

Parenteral 2500, 5000, 10000, 15000, 18000 anti-factor Xa units/0.2 mL for SC injection only Danaparoid (Orgaran)... [Pg.772]

Dalteparin, tinzaparin and danaparoid (an LMW heparanoid containing heparan sulfate, dermatan sulfate, and chondroitin sulfate that is no longer available in the United States), on the other hand, are specified in anti-factor Xa units. [Pg.765]

Common Name Danaparoid sodium Dermatan sulfate... [Pg.1190]

See also in sourсe #XX -- [ Pg.367 ]

See also in sourсe #XX -- [ Pg.244 , Pg.245 ]

See also in sourсe #XX -- [ Pg.148 ]

See also in sourсe #XX -- [ Pg.2 , Pg.2 , Pg.3 , Pg.29 , Pg.210 , Pg.212 ]

See also in sourсe #XX -- [ Pg.210 , Pg.212 ]

See also in sourсe #XX -- [ Pg.955 ]

See also in sourсe #XX -- [ Pg.270 ]

See also in sourсe #XX -- [ Pg.306 , Pg.310 ]

See also in sourсe #XX -- [ Pg.464 ]

See also in sourсe #XX -- [ Pg.290 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...